Oncotarget

Research Papers:

Metanephric adenoma: molecular study and review of the literature

Enrique Rodríguez-Zarco _, Jesús Machuca-Aguado, Laura Macías-García, Ana Vallejo-Benítez and Juan José Ríos-Martín

PDF  |  Full Text  |  How to cite  |  Order a Reprint

Oncotarget. 2022; 13:387-392. https://doi.org/10.18632/oncotarget.28192

Metrics: PDF 306 views  |   Full Text 818 views  |   ?  


Abstract

Enrique Rodríguez-Zarco1, Jesús Machuca-Aguado1, Laura Macías-García2, Ana Vallejo-Benítez3 and Juan José Ríos-Martín1

1 Pathology Department, University Hospital Virgen Macarena, Seville, Spain

2 School of Medicine, University of Seville, Seville, Spain

3 Pathology Department, Regional University Hospital of Malaga, Malaga, Spain

Correspondence to:

Enrique Rodríguez-Zarco, email: enriquerodriguezzarco@gmail.com

Keywords: metanephric adenoma; BRAF; renal neoplasms

Received: November 24, 2021     Accepted: January 17, 2022     Published: February 17, 2022

Copyright: © 2022 Rodríguez-Zarco et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Introduction: Metanephric adenoma (MA) is an uncommon benign tumor accounting for 0.2–0.7% of adult renal epithelial neoplasms. The clinical course is often indolent, but diagnosis should not be delayed since clinical symptoms (hematuria, fever, palpable abdominal mass, and flank pain) may be non-specific and overlap with those of a malign renal neoplasm. We report on 4 cases of AM, for which morphological and mutational analysis were performed.

Material and Methods: Immunohistochemical staining was performed on sections cut from paraffin blocks to assess expression of WT1, vimentin, racemase, CK7, CD10 and RCC. Testing for the BRAF gene mutation V600 was carried out using real-time PCR (Cobas® 4800).

Results: In all four cases, tumors were visible as well-circumscribed, non-encapsulated masses located in the renal cortex and extending towards the medulla. At immunohistochemical examination, tumor cells stained negative for CK7, CD10 and RCC and positive for both WT1 (nuclear, intense) and vimentin (cytoplasmic, intense, and diffuse). Molecular analysis revealed the BRAF gene mutation V600E in three cases and wild-type BRAF in the fourth.

Conclusions: BRAF molecular mutation analysis may aid diagnosis in cases with atypical histological features, especially in small incisional biopsies when reassessment of surgical treatment may be considered.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 28192